🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07523269
Recruiting Not applicable

WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control

NCT07523269 · tracked via the Priya Life Science USA tracker
Sponsor
Aktiia SA
Phase
Not applicable
Started
2026-04
Last updated
2026-04-13

Condition(s) studied

Hypertension (HTN)

Investigational drug(s) / intervention(s)

Aktiia G1 BP monitor for 12 monthsTraditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months

Aktiia G1 BP monitor for 12 months: These participants will receive an Aktiia G1 BP monitor and wear it through the entire 12-month study period.

Traditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months: These participants will receive a traditional BP monitor (validated upper arm cuff) to use for the 6 months comparison period. At the 6-month visit, they will return the traditional BP monitor and receive an Aktiia G1 BP monitor for the 6-month follow-up period.

Study summary

The WEARABLE-BP study will evaluate the clinical value of obtaining continual measurements using the Aktiia G1 Optical Blood Pressure Monitoring (OBPM) device in hypertensive patients, compared to using a traditional upper arm cuff for home BP monitoring.

The WEARABLE-BP study aims to compare the change in unattended automated office blood pressure from baseline to 6 months between two study groups: those given an Aktiia G1 BP monitor and those given a traditional upper arm BP cuff.

Eligibility

Sex
ALL
Min age
21 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 21 to 85 years. * Able to read and speak English. * Have an MGB provider and medical record number in EPIC * Study participants will wear the Aktiia bracelet for 6 months * Willing to attend two on-site study visits and comply with all study procedures. * Signed informed consent provided. * Own a smartphone with iOS or Android operating system. * Hypertensive with uncontrolled systolic blood pressure (SBP) \>135 mm Hg by unattended automated office measurement * Currently taking 0, 1 or 2 antihypertensive medications. Exclusion Criteria: * Severe hypertension (SBP \> 180 mmHg or DBP \> 120 mmHg). * Pregnant or breastfeeding. * Known severe heart failure (LVEF \< 35%). * Known severe valvular heart disease. * Known pheochromocytoma. * Known severe chronic kidney disease (CKD stage 4-5; eGFR \< 30 mL/min/1.73 m²). * Known uncontrolled hyperthyroidism or hypothyroidism. * Known severe diabetes (Hemoglobin A1c \> 10%). * Known resting heart rate \> 120 bpm. * Known persistent atrial fibrillation. * Known Raynaud's disease. * Known tremors or shivering disorders. * Known exfoliative skin diseases. * Known allergy to silicone. * Presence of lymphedema. * Paralysis of the arm. * Arm amputation. * Presence of implanted devices, such as a pacemaker, defibrillator, intravascular device, or arteriovenous fistula. * Upper arm circumference \< 22 cm or \> 42 cm. * Wrist circumference \> 23 cm. * Mastectomy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mass General Brigham Hospital Boston Massachusetts Recruiting

More Aktiia SA trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07523269 on ClinicalTrials.gov ↗ ← All trials in the USA